임상화학 분석기 : 시장 점유율 분석, 산업 동향 및 통계, 성장 예측(2024-2029년)

The Clinical Chemistry Analyzers Market size is estimated at USD 13.73 billion in 2024, and is expected to reach USD 16.94 billion by 2029, growing at a CAGR of 4.28% during the forecast period (2024-2029).

The healthcare system witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to reduce the risk of viral transmission as most chronic therapies were regarded as non-urgent. However, with the advent of the COVID-19 infection, large-scale clinical chemistry tests for people affected by the SARS-CoV-2 virus were performed. The clinical chemistry tests, along with the serological tests, helped in monitoring the overall health of the affected individuals during the pandemic period. An article published in the Journal of Clinical Chemistry and Laboratory Medicine in April 2020 listed several clinical chemistry tests for patients with COVID-19 in the emergency setting recommended by the IFCC. The tests also consider preanalytical, analytical, and post-analytical variables that can influence the test interpretation. Some of the clinical chemistry tests listed included albumin, lactate dehydrogenase (LD), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, among others. The increase in the utilization of these tests during the COVID-19 pandemic played a significant role in the growth of the market. However, the stabilizing cases of COVID-19 is expected to bring the clinical chemistry analyzer market at pre-pandemic level over the forecast period.

The major factors for the growth of the clinical chemistry analyzers market include the rising geriatric population, increasing prevalence of chronic diseases, growing importance and awareness of point-of-care testing, and rising technological advancements in clinical chemistry analyzers.

The clinical chemistry analyzers run assays on samples such as blood, plasma, urine, and cerebrospinal fluid to detect the presence of analytes relating to disease or drugs. According to the WHO article on aging and health published in October 2021, by the year 2030, around 1 in 6 people will be over the age of 60. The same source revealed that the number of people over the age of 60 will reach 1.4 billion in the year 2030, up from 1 billion in 2020. The numbers are further projected to rise to 2.1 billion by 2050. Thus, the increasing elderly population is vulnerable to several chronic diseases, resulting in high demand for clinical tests. Thus, the clinical chemistry analyzers market is expected to witness high growth over the forecast period.

Also, the rise in chronic diseases around the world is expected to add to the market's growth. According to the GLOBOCAN 2020 report, the total number of people in the world affected by cancer in 2020 accounted for around 19,292,789 cases. The number is estimated to rise to 28,887,940 cases by 2040. Besides, as per the IDF Diabetes Atlas Tenth Edition 2021, around 537 million adults all over the world were found to have diabetes in 2021, with the numbers projected to grow to 643 million by 2030 and 783 million by 2045. Clinical chemistry analyzers play a vital role in the assessment of such chronic conditions by measuring the lipids, electrolytes, plasma glucose levels, and other profiles of a wide range of components such as blood, serum, plasma, and cerebrospinal fluid, among others. Thus, the rising prevalence of chronic diseases is expected to increase the demand for clinical chemistry analyzers, thereby boosting the market growth.

Moreover, the product launches by the market players are likely to fuel the market's growth. For instance, in July 2022, EDAN Instruments, Inc. launched its POC fluorescence-based CO-OX blood gas and chemistry analysis system, i20, with the capacity to analyze over 45 parameters, covering everything from blood gases to electrolytes to CO-oximetry. Such product launches are expected to propel the growth of the studied market over the forecast period.

However, the lack of trained and qualified professionals and the high cost of clinical chemistry analyzers are expected to hinder the market's growth over the forecast period.

Clinical Chemistry Analyzers Market Trends

Analyzers in Product Type Segment are Expected to Witness Fastest Growth over the Forecast Period

The analyzers segment is expected to have the largest market share during the forecast period.

The analyzers are the instruments that examine the samples, such as blood serum and urine. Analyzers are witnessing high growth owing to the technological advancements in these instruments. Automation has become pervasive in clinical laboratories around the world. To reduce healthcare costs, laboratories have relied on automation to maintain profitability as well.

Furthermore, in September 2021, Roche Diagnostics India launched the Cobas pure integrated solutions analyzer with a smarter system that is particularly suitable for numerous laboratories and hospitals in India. The analyzer allows for better utilization of space and increased delivery of high-medical-value tests for greater patient benefits. Moreover, in May 2022, EKF Diagnostics launched its new EKF Link digital connectivity solution for the secure management of point-of-care (POC) analyzers and associated data on one centralized platform. Thus, the rising technological advancements in analyzers are expected to propel the growth of the analyzers segment in the clinical chemistry analyzers market.

Therefore, owing to the above-mentioned factors, the analyzers segment is expected to grow significantly over the forecast period.

North America is Expected to Hold Significant Market Share in the Forecast Period

The North American region is expected to contribute significantly to the market growth during the study period. The major factors contributing to the market growth in the region include the rising prevalence of chronic diseases; the increase in healthcare expenditures; and product innovations by the key market players in the region.

According to the CDC data on chronic diseases updated in July 2022, chronic diseases are the leading cause of death and disability every year in the United States. The rising number of chronic diseases in the nation adds to the growth of clinical chemistry analyzers in the North American region. The high burden of the target and chronic diseases in the region and increasing demand for early diagnostics are the other major factors that are driving the growth of the studied market in the North American region. For instance, according to the Canadian Cancer Society's 2021 report, about 229,200 new cancer cases will be diagnosed in Canada in 2021, and on average, 628 Canadians are diagnosed with cancer every day, which is further expected to increase in the future. Also, as per the same report, lung, breast, colorectal, and prostate cancer are the most diagnosed types of cancer in Canada (excluding non-melanoma skin cancer).

The major market players are launching new technologically advanced products into the market. For instance, in February 2021, Thermo Fisher Scientific partnered with Mindray to provide customers in the United States and Canada with two clinical chemistry analyzers for drug screening in clinical and forensic laboratories. Thermo Fisher and Mindray entered into an agreement to offer the USD FDA-cleared and Health Canada-approved BS-480 (400 tests/hour) and BA-800M (800 tests/hour) analyzers to toxicology labs.

Thus, owing to all the above-mentioned factors, North America is expected to hold the largest share of the clinical chemistry analyzers market.

Clinical Chemistry Analyzers Industry Overview

The clinical chemistry analyzers market studied is a fragmented market owing to the presence of various market players. Some of the market players are Abbott Laboratories, Danaher Corporation (Beckman Coulter, Inc.), Elitech Group, F.Hoffmann-La Roche Ltd., Horiba, Ltd., Johnson & Johnson, Mindray Medical International Limited, Siemens Healthcare Private Limited, Sysmex Corporation, and Thermo Fisher Scientific Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Geriatric Population and Increasing Prevalence of Chronic Diseases
  • 4.2.2 Increasing Importance and Awareness of Point-of-care Testing
  • 4.2.3 Rising Technological Advancements in Clinical Chemistry Analyzer
• 4.3 Market Restraints
  • 4.3.1 Lack of Trained and Qualified Professionals
  • 4.3.2 High Cost of Clinical Chemistry Analyzer Equipment
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Millions)

• 5.1 By Product Type
  • 5.1.1 Analyzers
  • 5.1.2 Reagents
  • 5.1.3 Others
• 5.2 By Types of Test
  • 5.2.1 Liver Panels
  • 5.2.2 Electrolyte Panels
  • 5.2.3 Thyroid Function Panels
  • 5.2.4 Lipid Profiles
  • 5.2.5 Others
• 5.3 By End User
  • 5.3.1 Hospital
  • 5.3.2 Diagnostic Laboratories
  • 5.3.3 Academic Institutes
  • 5.3.4 Others
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Abbott Laboratories
  • 6.1.2 Danaher Corporation (Beckman Coulter, Inc.)
  • 6.1.3 Elitech Group
  • 6.1.4 F. Hoffmann-La Roche Ltd.
  • 6.1.5 Horiba, Ltd.
  • 6.1.6 Johnson & Johnson
  • 6.1.7 Mindray Medical International Limited
  • 6.1.8 Siemens Healthcare Private Limited
  • 6.1.9 Sysmex Corporation
  • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS